Berlex’ YAZ Clears FDA For Contraception; April Launch Planned
This article was originally published in The Pink Sheet Daily
Executive Summary
A premenstrual dysphoric disorder indication for the low-dose version of Yasmin is still pending.
You may also be interested in...
Berlex’s Yaz Gains Acne Indication
The approval marks the third indication for the oral contraceptive.
Berlex’s Yaz Gains Acne Indication
The approval marks the third indication for the oral contraceptive.
Schering AG Sales BENEFIT From Betaseron Study
Sales of the multiple sclerosis drug Betaseron and the oral contraceptive Yasmin grew double digits in the first nine months of the year.